Veru (NASDAQ:VERU) Issues Earnings Results, Beats Expectations By $0.01 EPS

Veru (NASDAQ:VERU) announced its quarterly earnings results on Thursday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%.

Veru Stock Performance

VERU traded up $0.02 during trading on Friday, hitting $0.54. The stock had a trading volume of 1,855,548 shares, compared to its average volume of 6,253,218. The stock has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $0.77. The company has a market capitalization of $79.24 million, a PE ratio of -1.93 and a beta of -0.54. Veru has a twelve month low of $0.40 and a twelve month high of $1.92.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of Veru in a report on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.